BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12017495)

  • 21. Is there a common theme in the alternative medicine debate?
    Milstein M
    J Am Vet Med Assoc; 2005 Apr; 226(8):1294; author reply 1296-7. PubMed ID: 15844410
    [No Abstract]   [Full Text] [Related]  

  • 22. n-of-1 randomized controlled trials: an opportunity for complementary and alternative medicine evaluation.
    Johnston BC; Mills E
    J Altern Complement Med; 2004 Dec; 10(6):979-84. PubMed ID: 15673992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methodological issues and complementary therapies: researching intangibles?
    Carter B
    Complement Ther Nurs Midwifery; 2003 Aug; 9(3):133-9. PubMed ID: 12852929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Complementary and alternative medicine research and cooperative groups: can it happen?
    O'Mara A
    J Pediatr Oncol Nurs; 2006; 23(5):258-60. PubMed ID: 16902079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On equivalence trials and alternative medicine.
    Yueh B; Piccirillo JF
    Arch Otolaryngol Head Neck Surg; 2003 Apr; 129(4):403-4. PubMed ID: 12707185
    [No Abstract]   [Full Text] [Related]  

  • 26. Research-design issues in cancer-symptom-management trials using complementary and alternative medicine: lessons from the National Cancer Institute Community Clinical Oncology Program experience.
    Buchanan DR; White JD; O'Mara AM; Kelaghan JW; Smith WB; Minasian LM
    J Clin Oncol; 2005 Sep; 23(27):6682-9. PubMed ID: 16170176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Readers' and author's responses to "whatever happened to plausibility as the basis for clinical research and practice after EBM and CAM rushed in?".
    Young LJ
    MedGenMed; 2007; 9(2):57; author reply 57. PubMed ID: 17977087
    [No Abstract]   [Full Text] [Related]  

  • 28. Readers' and author's responses to "whatever happened to plausibility as the basis for clinical research and practice after EBM and CAM rushed in?".
    Varner J
    MedGenMed; 2007; 9(2):57; author reply 57. PubMed ID: 17977086
    [No Abstract]   [Full Text] [Related]  

  • 29. Readers' and author's responses to "whatever happened to plausibility as the basis for clinical research and practice after EBM and CAM rushed in?".
    Miller HL
    MedGenMed; 2007; 9(2):57; author reply 57. PubMed ID: 17977085
    [No Abstract]   [Full Text] [Related]  

  • 30. Readers' and author's responses to "whatever happened to plausibility as the basis for clinical research and practice after EBM and CAM rushed in?".
    Fahey SR
    MedGenMed; 2007; 9(2):57; author reply 57. PubMed ID: 17977084
    [No Abstract]   [Full Text] [Related]  

  • 31. Liabilities involved in conducting randomized clinical trials of CAM therapies in the absence of preliminary, foundational studies: a case in point.
    Margolin A
    J Altern Complement Med; 1999 Feb; 5(1):103-4. PubMed ID: 10100036
    [No Abstract]   [Full Text] [Related]  

  • 32. To forgive is human, to err divine.
    Benda W
    J Altern Complement Med; 2007 May; 13(4):395-6. PubMed ID: 17532728
    [No Abstract]   [Full Text] [Related]  

  • 33. Proof versus plausibility: rules of engagement for the struggle to evaluate alternative cancer therapies.
    Hoffer LJ
    CMAJ; 2001 Feb; 164(3):351-3. PubMed ID: 11232135
    [No Abstract]   [Full Text] [Related]  

  • 34. Complementary and alternative therapies: the power of randomization.
    Wild R
    J Soc Gynecol Investig; 2006 Jan; 13(1):1. PubMed ID: 16378909
    [No Abstract]   [Full Text] [Related]  

  • 35. Early phase methodology is needed in CAM and conventional research endeavors.
    Fønnebø V
    J Altern Complement Med; 2007 May; 13(4):397-8. PubMed ID: 17532729
    [No Abstract]   [Full Text] [Related]  

  • 36. Investigating CAM.
    Oppel LB
    CMAJ; 2003 Jun; 168(12):1527; author reply 1527-8. PubMed ID: 12796325
    [No Abstract]   [Full Text] [Related]  

  • 37. The importance of early phase research.
    Aickin M
    J Altern Complement Med; 2007 May; 13(4):447-50. PubMed ID: 17532739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Larger effect sizes were associated with higher quality ratings in complementary and alternative medicine randomized controlled trials.
    Bausell RB; Lee WL; Soeken KL; Li YF; Berman BM
    J Clin Epidemiol; 2004 May; 57(5):438-46. PubMed ID: 15196613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Future direction of complementary and alternative medicine (CAM) education and research.
    Wyatt G; Post-White J
    Semin Oncol Nurs; 2005 Aug; 21(3):215-24. PubMed ID: 16092810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A brief evidence-based review of two gastrointestinal illnesses: irritable bowel and leaky gut syndrome.
    Manahan B
    Altern Ther Health Med; 2004; 10(4):14. PubMed ID: 15285270
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.